Enterprise Value

90.43M

Cash

389.7M

Avg Qtr Burn

-25.95M

Short % of Float

9.59%

Insider Ownership

21.75%

Institutional Own.

65.62%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

ERAS-601 (SHP2 inhibitor) w/ cetuximab Details
Solid tumor/s, Cancer, Head and neck squamous cell carcinoma

Phase 1b

Data readout

ERAS-007 Details
Cancer, Colorectal cancer , BRAFm Colorectal Cancer

Phase 1b

Data readout

Naporafenib (pan-RAF inhibitor) w/ trametinib Details
Solid tumor/s, RAS Q61X solid tumors

Phase 1b

Initiation

Phase 1

Data readout

ERAS-007 Details
Non-small cell lung carcinoma

Failed

Discontinued

ERAS-007 + ERAS-601 Details
Solid tumor/s, Cancer

Failed

Discontinued